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abstract
PURPOSE To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-
free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma.
METHODS Eligible patients were randomly assigned to six cycles of IV paclitaxel 80 mg/m2 once per week with
intravenous (IV) carboplatin area under the curve 6 (IV carboplatin) versus IV paclitaxel 80mg/m2 once per week
with IP carboplatin area under the curve 6 (IP carboplatin) versus once every 3 weeks IV paclitaxel 135 mg/m2
over 3 hours day 1, IP cisplatin 75 mg/m2 day 2, and IP paclitaxel 60 mg/m2 day 8 (IP cisplatin). All participants
received bevacizumab 15 mg/kg IV every 3 weeks in cycles 2 to 22.
RESULTS A total of 1,560 participants were enrolled and had 84.8 months of follow-up. The median PFS
duration was 24.9 months in the IV carboplatin arm, 27.4 months in the IP carboplatin arm, and
26.2 months in the IP cisplatin arm. For the subgroup of 1,380 patients with stage II/III and residual
disease of 1 cm or less, median PFS was 26.9 (IV-carboplatin), 28.7 (IP-carboplatin), and 27.8 months
(IP cisplatin), respectively. Median PFS for patients with stage II/III and no residual disease was 35.9,
38.8, and 35.5 months, respectively. Median overall survival for all enrolled was 75.5, 78.9, and 72.9
months, respectively, and median overall survival for stage II/III with no gross residual disease was 98.8
months, 104.8 months, and not reached. Mean patient-reported Functional Assessment of Cancer
Therapy neurotoxicity scores (Gynecologic Oncology Group) were similar for all arms, but the mean Trial
Outcome Index of the Functional Assessment of Cancer Therapy–Ovary scores during chemotherapy
were statistically worse in the IP cisplatin arm.
CONCLUSION Compared with the IV carboplatin reference arm, the duration of PFS was not signiﬁcantly
increased with either IP regimen when combined with bevacizumab and was better tolerated than IP
cisplatin.
J Clin Oncol 37:1380-1390. © 2019 by American Society of Clinical Oncology
INTRODUCTION
Ovarian cancer incidence in 2018 was expected to be
22,240 with 14,070 deaths.1 This study was designed
to build on the advances seen with intraperitoneal (IP)
cisplatin and paclitaxel administration as demon-
strated by the Gynecologic Oncology Group (GOG)
protocol 172, where women with stage III disease and
completely resected disease survived a median of
127.6 months with IP chemotherapy compared with
82 months with intravenous (IV) cisplatin–based
chemotherapy.2-4 Despite the survival beneﬁt, less
than half of eligible women treated at National Cancer
Institute (NCI) comprehensive cancer centers re-
ceived this treatment secondary to toxicity and the
difﬁculty with administering IP therapy as reported by
Wright et al.5 The ovarian committee of the GOG de-
termined that a less complicated, less toxic, more
feasible outpatient regimen was needed to increase
access. The performance of phase I studies GOG-
9916, GOG-9917, and GOG-99216-8 helped to identify
tolerable IP chemotherapy regimens.
The community standard of carboplatin and paclitaxel
IV every 3 weeks was challenged by improved survival
demonstrated with weekly paclitaxel and every
3 weeks carboplatin in the Japanese Gynecologic
Oncology Group (JGOG) study 3016. This led to
selection of weekly paclitaxel and every 3 weeks
carboplatin as the control arm for the current study
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(GOG-252).9,10 In addition, a separate clinical trial, GOG-
262,11 was designed to conﬁrm the JGOG results in the US
population. Immediately before activation of GOG-252 and
GOG-262, the activity of bevacizumab in this patient
population was becoming evident. There was concern that
withholding bevacizumab would decrease enrollment and
adherence to the protocol and result in a biased survival
analysis because the availability of bevacizumab post-
recurrence may alter results.12-14 The preliminary results
from GOG-218 and the International Collaborative Ovarian
Neoplasm (ICON) trial ICON-7, which evaluated the ad-
dition of bevacizumab in primary therapy of ovarian cancer,
were completed at approximately the same time of opening
GOG-252.15,16 Therefore, bevacizumab was added to all
arms of the current trial because it was assumed that in-
cluding bevacizumab in each study regimen would not
appreciably alter the relative effectiveness of the chemo-
therapy regimens.
METHODS
Eligible patients with newly diagnosed stage II through IV
epithelial ovarian, fallopian tube, or primary peritoneal
cancer were enrolled within 12 weeks of surgery for staging
and maximal cytoreduction. A GOG performance status
score of 0 to 2 was required. Eligibility included adequate
laboratory assessment, including creatinine levels no
higher than the upper limit of normal, and patients could
not have any contraindications to bevacizumab (see the
Data Supplement for full eligibility criteria). All patients
provided written institutional review board–approved in-
formed consent.
Study Design
GOG-252 is an open-label, randomized phase III clinical
trial to determine whether IP chemotherapy would improve
progression-free survival (PFS) compared with the refer-
ence IV arm paclitaxel 80 mg/m2 once per week with IV
carboplatin area under the curve (AUC) 6. The study was
originally designed for patients with stage II/III optimally
resected disease. An exploratory objective was added to
include patients with suboptimal stage III and stage IV
disease. The experimental IP arms were IV paclitaxel
80 mg/m2 once per week with IP carboplatin AUC 6 (IP
carboplatin) and IV paclitaxel 135mg/m2 over 3 hours day 1,
day 2 IP cisplatin 75 mg/m2, and day 8 IP paclitaxel
60 mg/m2 (IP cisplatin). All arms delivered bevacizumab
15 mg/kg IV day 1 cycles 2 to 22 (NSC #704865, IND
#7921; Fig 1). Secondary objectives were improvement in
overall survival (OS), toxicity of each arm, and patient-
reported outcomes (PROs) to determine quality of life
while on each regimen.
Disease Assessment
Computed tomography scans or magnetic resonance im-
aging of the abdomen and pelvis was obtained for docu-
mentation of measurable disease but was not the basis for
stratiﬁcation or eligibility. Imaging (computed tomography
scan or magnetic resonance imaging), cancer antigen 125
measurement, and physical examination were to be re-
peated after treatment cycles 6, 12, and 22 of chemo-
therapy and every 6 months until 5 years from enrollment
and then annually until progression or death. Toxicity
monitoring and dose adjustments are provided in the Data
Supplement.
Quality-of-Life Assessments and Instruments
PROs were assessed at six time points: before random
assignment, before the fourth cycle (9 weeks after starting
treatment), before the seventh cycle (18 weeks after
starting treatment), before the 13th cycle (36 weeks after
starting treatment), before the 21st cycle (60 weeks after
starting treatment), and 84 weeks after starting treatment.
The Trial Outcome Index of the Functional Assessment of
Cancer Therapy–Ovary (FACT-O TOI) was used to capture
patient-reported assessments of their own physical and
functional well-being and additional concerns related
speciﬁcally to ovarian cancer.14,17,18 Lower FACT-O TOI
scores represent poorer quality of life. In addition, the four-
item FACT/GOG-Neurotoxicity subscale (short), the four-
item FACT/GOG-Abdominal Discomfort subscale, the
13-item Functional Assessment of Chronic Illness Therapy-
Fatigue subscale, and a single-item nausea question were
used to capture the patient’s self-reported chemotherapy-
induced neuropathy, abdominal discomfort, and fatigue,
respectively. All measures were scored using a 5-point
scale (not at all = 0, a little bit = 1, somewhat = 2, quite
a bit = 3, very much = 4).
Statistical Considerations
Study treatment was assigned using a minimization pro-
cedure.19 This procedure randomly allocated one of the
three study treatments such that there would be nearly an
equal number of patients who received each study treat-
ment within the following patient-level characteristics:
cancer stage and residual disease status (II v III with no
gross residual v III with gross residual v IV). The primary
study end point was PFS calculated from each patient’s
enrollment date to the onset of either clinically evident
progression or death as a result of any cause, whichever
occurred ﬁrst. The onset of clinical progression was deﬁned
as either radiographic evidence of increasing disease on
the basis of Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1, a global deterioration of health, or
a rise in cancer antigen 125 level using the Gynecologic
Cancer Intergroup criteria.20,21 The duration of PFS was
censored at the date of last contact for those patients who
remained alive and free of progression.19 The trial was
designed to establish the superiority of each of the IP
regimens compared with the IV regimen using a stratiﬁed
log-rank test.22 The two IP regimens are compared with
each other if superiority is found. The null hypotheses (ie,
equivalence of the hazard of progression or death between
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each of the two IP regimens compared with the IV regimen)
was assessed with a stratiﬁed log-rank test.22 The primary
analyses of PFS included all patients enrolled in the study
regardless of eligibility or compliance with their assigned
study regimen intention to treat. The design also allowed for
comparing treatments within the subgroup of individuals
with International Federation of Gynecology and Obstetrics
stage II or III disease and no residual disease greater than 1
cm. The overall type I error for these hypotheses was to be
limited to 5% (one tail), after accounting for the correlation
between hypothesis tests because of a common reference
group (IV regimen), and testing within a subgroup (stage II/III
optimally resected). The study was considered sufﬁciently
mature for a ﬁnal analysis when at least 360 ﬁrst pro-
gressions or death (PFS events) had occurred among those
allocated to the reference regimen IV carboplatin. This
sample size provides approximately 80% power for
detecting a 20% decrease in the hazard of ﬁrst progression
or death when each IP regimen is compared with the IV
regimen in the intention-to-treat population (Data Sup-
plement). NCI Common Terminology Criteria for Adverse
Events (version 3.0) was used to grade the adverse
events.23 Summaries and analyses of adverse events in-
clude only those patients who at least initiated their
assigned study treatment.
For the analysis of PROs, a mixed-effects model was used
to compare the mean PRO scores between treatment
groups (see Data Supplement for a description of all
measures). If there was evidence of a time-dependent
treatment effect, Hochberg step-down procedure was
used to control the type I error of between-treatment
comparisons over the individual assessment times.24 The
least squares mean estimates were obtained from a ﬁtted
mixed-effects model that adjusted for pretreatment score
(baseline score) and patient age at the time of enrollment.
The treatment differences were estimated from the ﬁtted
Participants enrolled from 213 
clinics in the United States 
(N = 1,560)
Randomly assigned treatment
IV carboplatin                             (n = 521)
Paclitaxel 80 mg/m2 IV
  on days 1, 8, and 15
 Plus carboplatin AUC 6  IV on day 1
 every 21 days for cycles 1-6
 Plus bevacizumab 15 mg/kg IV
 every 21 days for cycles 2-22  
Initiated study treatment and 
   evaluated for adverse events   (n = 511)
 Did not initiate treatment                       (n = 10)
Initiated study treatment and 
   evaluated for adverse events  (n = 510)
  Did not initiate treatment            (n = 8)
Initiated study treatment and 
   evaluated for adverse events    (n = 508)
  Did not initiate treatment             (n = 13)
Evaluated for PFS and OS        (n = 521)
Alive and progression free      (n = 135)
Alive at last contact                (n = 255)
Evaluated for PFS and OS        (n = 518)
  Alive and progression free            (n = 147)
  Alive at last contact                 (n = 262)
Evaluated for PFS and OS            (n = 521)
  Alive and progression free     (n = 139)
  Alive at last contact                   (n = 249)
IP carboplatin                             (n = 518)
 Paclitaxel 80 mg/m2 IV
  on days 1, 8, and 15
 Plus carboplatin AUC 6 IP on day 1
    every 21 days for cycles 1-6
 Plus bevacizumab 15 mg/kg IV
    every 21 days for cycles 2-22 
IP cisplatin                                    (n = 521)
 Paclitaxel 135 mg/m2 IV on day 1
 Plus cisplatin 75 mg/m2 IP on day 2
 Plus paclitaxel 60 mg/m2 IV on day 8
    every 21 days for cycles 1-6
 Plus bevacizumab 15 mg/kg IV
    every 21 days for cycles 2-22
FIG 1. CONSORT diagram that accounts for all participants and the chemotherapy regimen arms to which they were randomly assigned.
Crossover during treatment to the IV arm occurred in 16% of those randomly assigned to the IP carboplatin arm and 28% of those randomly
assigned to the IP cisplatin arm. Taxotere was substituted for paclitaxel in 7% of those in the IV and IP carboplatin arms and 5% of those in the
IP cisplatin arm. There was discontinuation of bevacizumab during the concurrent chemotherapy administration of the ﬁrst six cycles in 15%
of participants in the IV and IP carboplatin arms and 30% of participants in the IP cisplatin arm. Themedian number of cycles of bevacizumab was
20 for those in the IV carboplatin arm, 19 in the IP carboplatin arm, and 17 in the IP cisplatin arm. Reason for discontinuation of study regimen was
completion of therapy in 51% of participants in the IV carboplatin arm, 49% in the IP carboplatin arm, and 45% in the IP cisplatin arm.
Toxicity caused discontinuation in 24%, 28%, and 29%, respectively, and refusal was 6%, 6%, and 9%, respectively. Disease progression or
death was cause for discontinuation in 16%, 13%, and 13%, respectively. The delivery of six cycles of any platinum agent was 90% in the IV and IP
carboplatin arms and 84% in the IP cisplatin arm. Day 8 paclitaxel was delivered to 66% of participants in the IV or IP carboplatin arms for all
six cycles and only 59% in the IP cisplatin arm. Four cycles of day 8 paclitaxel was received by 85% of participants in the IV and IP carboplatin
arms and 80% of those in the IP cisplatin arm. In the IV and IP carboplatin arms, only 40% of participants received day 15 paclitaxel through six
cycles, and 60% received it through four cycles, whereas 80% received two cycles. AUC, area under the curve; OS, overall survival; PFS,
progression-free survival.
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mixed-effects models and presented with the corre-
sponding 99% CIs. The effect of study treatments on
nausea was summarized with patients’ complaints of
somewhat nauseous or having worse nausea and was
evaluated with the generalized estimating equation method
that adjusted for baseline score and patient age. To control
the overall type I error to be 5% for the entire family of PRO
hypotheses, a signiﬁcance level for each of the ﬁve PRO
measures was set to 1% (two sided) for the global treatment
comparison. As a result, the reported P values were
Bonferroni adjusted. Compliance across regimens was
assessed with methods using generalized estimating
equations.
RESULTS
This report includes an accounting of all patients who were
enrolled and randomly assigned. In total, 1,560 patients
with epithelial ovarian, fallopian tube, and peritoneal car-
cinoma were enrolled between July 27, 2009, and No-
vember 30, 2011. The study was designed to determine
whether IP chemotherapy improves PFS in optimally
resected (# 1 cm) advanced-stage epithelial ovarian, fal-
lopian tube, and peritoneal carcinoma (Fig 1). The data-
base was frozen and locked for this analysis on November
27, 2018, and there have been 84.8 months of follow-up.
Participants were a median age of 58 years. Seventy-two
percent had primary tumors with a high-grade serous
histology, 58% had only microscopic residual disease (no
gross residual by surgical report), 93% had residual tu-
mor of 1 cm or less, and 84% had stage III disease
(Table 1).
Efﬁcacy
At the time of these analyses, 1,139 of all the enrolled
patients (73%) experienced disease progression or death.
The median duration of PFS was 24.9 months for patients
randomly assigned to IV carboplatin, 27.4 months for those
assigned to IP carboplatin, and 26.2 months for those
assigned to IP cisplatin (Fig 2). Compared with IV carbo-
platin, the hazard of ﬁrst progression or death was 7.5%
lower (hazard ratio [HR], 0.925; 95% CI, 0.802 to 1.07) for
the IP carboplatin arm and 2.3% lower (HR, 0.977; 95%CI;
0.847 to 1.13) for the IP cisplatin arm. There was no
statistically signiﬁcant difference in PFS between the IV
regimen and either of the IP regimens.
Among the 1,380 participants who had stage II and III and
optimally resected to 1 cm or less residual disease per
surgeon, 973 (71%) experienced progression or death. In
this subgroup of patients, the median duration of PFS was
26.9 months for IV carboplatin, 28.7 months for IP car-
boplatin (HR, 0.921; 95% CI, 0.789 to 1.07), and
27.8 months for IP cisplatin (HR, 0.966; 95% CI, 0.828 to
1.13). There was no statistically signiﬁcant difference in
PFS between the IV regimen and either of the IP regimens
in this subgroup of patients (Fig 3).
There were 870 participants with stage II or III and no gross
residual disease documented at the completion of surgery,
of whom 534 (61%) experienced disease progression or
death. In this subgroup of patients, the median duration of
PFS was 35.9 months for IV carboplatin, 38.8 months for IP
carboplatin, and 35.5 months for IP cisplatin. There was no
statistically signiﬁcant difference in PFS between the IV
regimen and either of the IP regimens in this subgroup of
patients (Fig 4).
For all randomly assigned participants, with 49% alive after
a median follow-up of 84.8 months, the median OS was
75.5 months in the IV carboplatin arm and 78.9 and
72.9 months for the IP carboplatin and IP cisplatin arms,
respectively. Relative to the IV carboplatin group, the
hazard of death was similar in the IP carboplatin arm (HR,
0.949; 95% CI, 0.799 to 1.128) and IP cisplatin arm (HR,
1.05; 95% CI, 0.884 to 1.24; Fig 5). OS for stage III op-
timally resected to 1 cm or less residual disease was 74.6,
78.2, and 74.1 months, respectively (Data Supplement).
For stage II/III optimally resected with 1 cm or less residual
disease, the OS was 80.0, 84.7, and 76.3 months, re-
spectively (Data Supplement). For stage II/III with no gross
residual disease, the median OS was 98.8 months for IV
carboplatin, 104.8 months for IP carboplatin, and not
reached for IP cisplatin (Data Supplement).
Safety
Twenty-ﬁve deaths were attributed, in part, to toxicity (eight
IV carboplatin, seven IP carboplatin, 10 IP cisplatin), ﬁve of
which were during cycle 1, eight during cycles 2 to 4, seven
during cycles 5 to 6, and ﬁve after completing cycle 6.
Three deaths were cardiac, one CNS, four sudden death
not otherwise characterized, seven associated with sepsis
during the ﬁrst six cycles, two associated with GI perfora-
tions, and the remaining deaths as a result of disease
progression or an unspeciﬁed cause (Table 2).
Grade 3 or worse infections were higher (P = .008 global
exact test) in the IP arms (11.5% for IV carboplatin, 17.2%
for IP carboplatin, and 17.7% for IP cisplatin). Growth
factors were added, and day 15 paclitaxel was discontinued
in 20% at cycle 2 in the IV and IP carboplatin arms. Another
20% discontinued paclitaxel by cycle 4 and added growth
factors (see Data Supplement with regard to dose adjust-
ments). There was no evidence of an increase in GI per-
forations, ﬁstulas, or necrosis with IP chemotherapy.
Nausea and vomiting grade 3 or worse was more common
(P, .005) in the IP cisplatin arm at 11.0% compared with
the IV carboplatin arm at 5.1% and the IP carboplatin arm
at 4.7%. Grade 2 or worse sensory neuropathy was similarly
high in all arms, with the IV carboplatin and weekly pac-
litaxel arm at 30%, and grade 3 or worse sensory neu-
ropathy was similar in all arms at 5.7%, 4.5%, and 5.5%,
respectively. Grade 3 or worse hypertension was signiﬁ-
cantly worse (P , .005) in the IP cisplatin arm at 20.5%
compared with 11.9% and 14.3% in the IV carboplatin and
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IP carboplatin arms, respectively. Grade 2 or worse CNS
ischemia was seen in the IP cisplatin arm at 2.0% and led
to one death, whereas 0.8% in the IV carboplatin and
0.6% in the IP carboplatin arms had at least grade 2 CNS
ischemic events reported. Grade 3 or worse thrombotic
events, including those that resulted from vascular
access devices, occurred in 6.3%, 8.4%, and 9.0%,
respectively.
PROs
A total of 1,437 patients (92%) completed a baseline PRO
and at least one follow-up PRO. Completion rates were high
TABLE 1. Patient Characteristics
Randomized Treatment
IV Carboplatin IP Carboplatin IP Cisplatin Total
Characteristic No. % No. % No. % No. %
Age-group, years
, 40 27 5.2 13 2.5 18 3.5 58 3.7
40-49 101 19.4 77 14.9 95 18.2 273 17.5
50-59 187 35.9 178 34.4 199 38.2 564 36.2
60-69 152 29.2 181 34.9 151 29.0 484 31.0
70-79 51 9.8 64 12.4 53 10.2 168 10.8
$ 80 3 0.6 5 1.0 5 1.0 13 0.8
Ethnicity
Hispanic 17 3.3 21 4.1 23 4.4 61 3.9
Non-Hispanic 469 90.0 458 88.4 462 88.7 1,389 89.0
Other/unspeciﬁed 35 6.7 39 7.5 36 6.9 110 7.1
Race
Asian 15 2.9 15 2.9 17 3.3 47 3.0
Black/African American 17 3.3 17 3.3 17 3.3 51 3.3
American Indian/Alaskan Native 2 0.4 2 0.4 2 0.4 6 0.4
Native Hawaiian/Paciﬁc Islander 1 0.2 1 0.2 0 0 2 0.1
White 473 90.8 478 92.3 476 91.4 1,427 91.5
Other/unspeciﬁed 13 2.5 5 1.0 9 1.7 27 1.7
FIGO stage
II 56 10.7 56 10.8 51 9.8 163 10.4
III 441 84.6 432 83.4 432 82.9 1,305 83.7
IV 24 4.6 30 5.8 38 7.3 92 5.9
Size of residual disease
Microscopic only 297 57.0 297 57.3 306 58.7 900 57.7
0 , diameter # 1 cm 182 34.9 189 36.5 182 34.9 553 35.4
Diameter . 1 cm 42 8.1 32 6.2 33 6.3 107 6.9
Histology/grade
Serous/1 20 3.8 12 2.3 27 5.2 59 3.8
Serous/2 43 8.3 36 6.9 35 6.7 114 7.3
Serous/3 370 71.0 379 73.2 377 72.4 1,126 72.2
Endometrioid 5 1.0 2 0.4 4 0.8 11 0.7
Clear cell 32 6.1 29 5.6 26 5.0 87 5.6
Mucinous 2 0.4 5 1.0 5 1.0 12 0.8
Other/not speciﬁed 48 9.2 55 10.6 47 9.0 150 9.6
Total 521 33.4 518 33.2 521 33.4 1,560 100.0
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; IP, intraperitoneal; IV, intravenous.
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during active and maintenance therapy, although the
overall completion rate was slightly lower in the IP cisplatin
arm throughout the study. Before cycle 4, PROs for IP
cisplatin were 5.9 points lower (99%CI, 3.7 to 8.1; adjusted
P , .001) on the basis of the FACT-O TOI compared with
those for IV carboplatin and 3.7 points lower (99% CI, 1.4 to
6.0; adjusted P = .003) than those for IP carboplatin. Al-
though all patients reported increased neurotoxicity during
treatment, those in the IP cisplatin arm experienced
signiﬁcantly worse symptoms at cycle 13 compared with IV
carboplatin (1.9 points lower; 99% CI, 1.1 to 2.6; adjusted
P, .001) and IP carboplatin (1.2 points lower; 99% CI, 0.4
to 2.0; adjusted P = .005). Neurotoxicity symptoms did not
recover to baseline even 6 months after maintenance
therapy among all study arms (Data Supplement). Ab-
dominal discomfort improved across regimens during
chemotherapy, but improvement was signiﬁcantly slower
for IP cisplatin compared with IV carboplatin (1.5 points
1.0
Treatment Group
1: IV carboplatin
2: IP carboplatin
3: IP cisplatin
325
322
326
459
464
457
26.9
28.7
27.8
Events Total Median 
(months)
PF
S 
(p
ro
po
rti
on
)
Time Since Random Assignment (months)
0.8
0.6
0.4
0.2
0
459
464
457
1
2
3
386
392
372
244
264
256
171
185
171
140
156
142
115
136
123
93
109
104
57
60
57
13
18
16
12 24 36 48 60 72 84 96
No. at risk
FIG 3. Progression-free survival (PFS) of
participants with optimally resected stage
II/III with 1 cm or less residual disease per
surgeon. In the 1,380 participants eval-
uated, 973 (71%) had a median PFS of
26.9 months in the intravenous (IV) car-
boplatin arm, 28.7 months in the in-
traperitoneal (IP) carboplatin arm (hazard
ratio, 0.921; 95% CI, 0.789 to 1.07), and
27.8 months in the IP cisplatin arm
(hazard ratio, 0.966; 95% CI, 0.828 to
1.13). There was no statistically signiﬁcant
difference in PFS between the IV regimen
and either of the IP regimens in this
subgroup of patients.
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FIG 2. Progression-free survival (PFS) of all
randomly assigned participants. In the
overall intention-to-treat population of 1,560
patients, 1,139 (73%) experienced pro-
gression. Compared with intravenous (IV)
carboplatin, the hazard of ﬁrst progression
or death was 7.5% lower (hazard ratio,
0.925; 95% CI, 0.802 to 1.07) for the in-
traperitoneal (IP) carboplatin arm and 2.3%
lower (hazard ratio, 0.977; 95% CI, 0.847 to
1.13) for the IP cisplatin arm. There was no
statistically signiﬁcant difference in PFS
between the IV regimen and either of the IP
regimens.
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lower; 99% CI, 1.0 to 2.1; adjusted P , .001) and IP
carboplatin (0.9 points lower; 99% CI, 0.3 to 1.5; adjusted
P = .005). Furthermore, before cycle 7, patients in the IP
cisplatin and IP carboplatin arms reported signiﬁcantly
more abdominal discomfort than those who received the IV
regimen (P = .006 and .002, respectively). The single item
“I have nausea”was signiﬁcantly worse for patients in the IP
cisplatin arm compared with IV carboplatin (0.5 points
higher; 99% CI, 0.3 to 0.7; adjusted P , .001) and IP
carboplatin (0.4 points higher; 99% CI, 0.2 to 0.6; adjusted
P , .001). There were no between-arm differences for
fatigue in chemotherapy or maintenance therapy PROs.
DISCUSSION
The primary outcomemeasure was an improvement in PFS
for experimental IP chemotherapy arms compared with the
reference arm of every 3 weeks IV carboplatin and IV
bevacizumab and weekly paclitaxel. The intention-to-treat
analysis shows no statistical difference for PFS among the
arms overall or in any subgroup evaluated. Of note, the PFS
of patients with optimally resected 1 cm or less residual
stage III disease was 24.9 to 27.1 months (Data Supple-
ment), which is better than that seen in GOG-172,2,3 where
the IV and IP arms showed a PFS of 18.3 and 23.8 months,
respectively. In addition, the current study had an OS for
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FIG 5. Overall survival (OS) by randomized
treatment of all enrolled patients. Forty-nine
percent of participants were alive after
a median follow-up of 84.8 months. Relative
to the intravenous (IV) carboplatin arm, the
hazard of death was similar in the in-
traperitoneal (IP) carboplatin arm (hazard
ratio, 0.949; 95% CI, 0.799 to 1.128) and in
the IP cisplatin arm (hazard ratio, 1.05; 95%
CI, 0.884 to 1.24). OS for stage II/III with no
gross residual disease was 98.8 months for
IV carboplatin; 104.8 months for IP carbo-
platin; and yet to be determined for IP cis-
platin, which needs a longer follow-up.
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FIG 4. Progression-free survival (PFS) of
participants with stage II/III with no gross re-
sidual disease. There were 870 participants
with stage II or III and no gross residual dis-
ease documented at the completion of surgery
of whom 534 (61%) experienced disease
progression or death. AdjustedHR (95%CI) of
PFS for intraperitoneal (IP) carboplatin vs.
intravenous (IV) carboplatin 5 0.92 (0.75 –
1.13). Adjusted HR (95% CI) of PFS for IP
cisplatin vs. IV carboplatin 5 0.97 (0.79 –
1.19). There was no statistically signiﬁcant
difference in PFS between the IV regimen and
either of the IP regimens in this subgroup of
patients.
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stage III optimally resected to 1 cm or less of 74.1 to
78.2 months (Data Supplement), which compares favor-
ably to that of GOG-172, where survival was 49.7 and
65.6 months in the IV and IP arms, respectively. In the
current study, 57% of the patients with stage II/III disease
were classiﬁed as having R0 (no residual disease), and their
OS was 98.8months for IV carboplatin, 104.8 months for IP
carboplatin, and not reached for IP cisplatin (Data Sup-
plement). This compares favorably with an ancillary anal-
ysis of patients with no gross residual disease in GOG-114
and GOG-172 treated with IP chemotherapy, where the
median OS was 110 months.2 This comparison brings use
of bevacizumab maintenance into question for this par-
ticular population, although it must be acknowledged that
this observation is based on cross-study comparisons. It
should be noted that the IP carboplatin arm was very well
tolerated (Table 2) and that only grade 3 infections and
abdominal pain were worse than in the IV reference arm.
There were 178 patients with surgically resected sub-
optimal stage III and IV disease enrolled as an exploratory
objective, and the results did not show a beneﬁt of IP
chemotherapy. The IV carboplatin arm demonstrated a PFS
of 16.9 months and OS of 55.5 months (Data Supplement),
which compares favorably with the GOG-21815 results of
a PFS of 14 months and OS of 39 months and the GOG-
26211 PFS of 14.7 and OS of 40.2 months. The explanation
of these improved results could be secondary to the re-
quired primary surgical resection.
On June 13, 2018, the Food and Drug Administration
approved the administration of bevacizumab in combina-
tion with carboplatin and paclitaxel on the basis of GOG-
218.15 The current study included bevacizumab therapy,
and participants had excellent PFS and OS in all subgroups
enrolled. The administration of paclitaxel once per week at
80 mg/m2 versus every 3 weeks paclitaxel at 175 mg/m2
has conﬂicting data. The JGOG study favored weekly
dosing,16 whereas the ICON-8 Gynecologic Cancer In-
tergroup study reported by Clamp et al25 at the European
Society of Medical Oncology meeting did not demonstrate
a beneﬁt of weekly paclitaxel administration compared with
every 3 weeks. The secondary analysis of GOG-262 by
Chan et al11 suggests that when bevacizumab is added,
then weekly paclitaxel shows no advantage compared with
the use of conventional every-3-week dosing. The ad-
ministration of all chemotherapy every 3 weeks is more
convenient and has less sensory neuropathy.11
The modiﬁcation of the cisplatin dose from 100 mg/m2
down to 75 mg/m2 and the reduction in paclitaxel dose to
135 mg/m2 over 3 hours instead of 24 hours to decrease
toxicity and allow more tolerable outpatient administration
may have compromised the efﬁcacy of the IP cisplatin arm
overall. In addition, the interaction between cisplatin and
bevacizumab increased hypertension, and more partici-
pants (30%) discontinued bevacizumab and received
fewer cycles of chemotherapy (84%) in the IP cisplatin arm
because of this toxicity. Dropping bevacizumab may im-
prove tolerance of the modiﬁed IP cisplatin arm and allow
more patients to complete the recommended cycles, unlike
in GOG-172 where only 42% of patients received six cycles
of IP cisplatin. Nonetheless, data from the current study
suggest no advantage to the use of the modiﬁed IP cisplatin
regimen compared with the more conventional IV drug
administration.
All arms of the current study compare favorably with hy-
perthermic IP chemotherapy where the PFS was
14.2 months and OS 33.9 months for patients with stage III
TABLE 2. Patients Who Experienced Selected Adverse Events by Grade and Randomized Treatment
Grade, %
IV Carboplatin (n = 511) IP Carboplatin (n = 510) IP Cisplatin (n = 508)
Adverse Event 2 3 4/5 2 3 4/5 2 3 4/5 P*
Hemoglobin 58.5 24.7 2.0 56.7 24.1 2.2 50.4 16.1 1.8 , .001
Neutrophils 19.8 45.6 26.4 20.0 44.9 23.1 21.1 33.5 30.8 .031
Platelets 16.8 12.9 4.7 19.0 11.6 3.5 7.3 5.5 0.6 , .001
Nausea/vomiting 16.8 4.7 0.4 20.0 4.7 0 25.8 10.8 0.2 , .001
Infections 33.7 10.2 1.4 34.3 16.1 1.2 29.6 17.0 0.8 .008
GI leak, perforation, or ﬁstula 1.6 2.9 2.4 1.2 3.1 0.6 1.4 3.2 1.2 .492
Thrombus 2.0 2.2 4.1 1.4 4.9 3.5 1.6 4.9 4.1 .206
Hypertension 17.0 11.4 0.6 15.3 13.5 0.8 17.0 18.7 1.8 , .001
Sensory neuropathy 24.1 5.5 0.2 22.6 4.5 0.0 21.3 5.5 0.0 .663
CNS ischemia 0.4 0.4 0.0 0.0 0.2 0.4 0.2 1.0 0.8 .058
NOTE. This summary of adverse events does not include 31 patients who did not initiate their assigned study treatment.
Abbreviations: IP, intraperitoneal; IV, intravenous.
*Nominal P value for a test of the null hypothesis that the probability of a grade 3 or worse adverse event is equal over the three treatments.
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resected to 1 cm or less disease.26 In addition, Intraperitoneal
Therapy for Ovarian Cancer With Carboplatin (iPocc), a study
conducted by the Gynecologic Cancer Intergroup and JGOG
that will be reported in 2020, is comparing weekly IV paclitaxel
with IP versus IV carboplatin without bevacizumab. The re-
sults of iPocc should provide additional insight into the role of
IP therapy in the context of weekly IV paclitaxel andmay clarify
the confounding role of bevacizumab in interpreting the data
fromGOG-252. In that regard, it is possible that the addition of
bevacizumab interacts with chemotherapy, which makes any
differences between arms not evident.
The optimal maintenance strategy in the ﬁrst-line setting is
under active investigation. Genomic mutation analysis has
not yet been performed on the participants of GOG-252, but
this will be an important area of future research, especially
as it relates to the use of inhibitors of poly (ADP-ribose)
polymerase (PARP). In that regard, the PARP inhibitor
olaparib is now preferred over maintenance bevacizumab
in genomic BRCA1 and BRCA2 mutation carriers and for
tumors that harbor somatic BRCA1 or BRCA2mutations.27
Concurrent administration of bevacizumab and PARP
inhibitors as maintenance therapy is under investiga-
tion in the PAOLA-1 study, which is set to report in 2019
(ClinicalTrials.gov identiﬁer: NCT02477644). Homologous
repair deﬁciency testing on tumors is another potential tool
to select treatment with PARP inhibitors. Interest also exists
in using IP cisplatin in these patients because of their DNA
repair deﬁciency and excellent survival outcomes with high-
dose cisplatin delivered through the IP route. In particular,
Lesnock et al28 determined in a secondary analysis of GOG-
172 that aberrant BRCA1 expression improves survival
from 47months when treated with IV cisplatin to 84months
when treated with IP cisplatin. Translational studies using
GOG-252 specimens may identify subsets of patients who
may beneﬁt from IP therapy.
In conclusion, the beneﬁt of IP administration of chemo-
therapy was not evident in this large randomized clinical trial.
The toxicity and PROs support the decision to select the IV
carboplatin AUC 6 day 1, dose-dense paclitaxel 80 mg/m2 IV
once per week, and bevacizumab 15mg/kg IV day 1 given in
3-week cycles, and there is no evidence that this compro-
mises PFS or OS. The use of IP chemotherapymay still be an
option in select patients who are homologous repair de-
ﬁciency positive with no gross residual disease, but the
original GOG-172 dose and schedule should be considered
in that case and may be used without bevacizumab.
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